Triptorelin
CLINICAL USE
Advanced prostate cancer Endometriosis Precocious puberty Uterine fibroids prior to surgery
DOSE IN NORMAL RENAL FUNCTION
3–3.75 mg every 4 weeks; depends on preparation 11.25 mg every 3 months
PHARMACOKINETICS
Molecular weight : 1311.4 %Protein binding : No data %Excreted unchanged in urine : 3–14 Volume of distribution (L/kg) : 92.4–115.8 litres half-life – normal/ESRD (hrs) : 7.5/Unchanged DOSE IN RENAL IMPAIRMENT
GFR (mL/MIN)
20 to 50 : Dose as in normal renal function 10 to 20 : Dose as in normal renal function, but monitor carefully <10 : Dose as in normal renal function, but monitor carefully DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES
CAPD : Unlikely to be dialysed. Dose as in normal renal function, but monitor carefully HD : Unlikely to be dialysed. Dose as in normal renal function, but monitor carefully HDF/high flux : Unknown dialysability. Dose as in normal renal function, but monitor carefully CAV/VVHD : Unlikely to be dialysed. Dose as in normal renal function, but monitor carefully IMPORTANT DRUG INTERACTIONS
Potentially hazardous interactions with other drugs None known ADMINISTRATION
Reconstition
With 2 mL diluent provided Route
SC, IM Rate of Administration
– Comments
– .
See how to identify renal failure stages according to GFR calculation
See how to diagnose irreversible renal disease
Home
